Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation develops and manufactures minimally invasive spinal implants and interventional pain management technologies for spinal surgery. News about ASAPF commonly covers product launches, patent issuances and commercialization updates across the company's spine portfolio, including DEXA Technology bone density-matched implants, ZIP implants, SiLO systems, Hydra A.E.R.O. facet fusion products and Aurora Biologics.
Recurring updates also include financial results, sales-force and product-adoption commentary, medical meeting participation and intellectual-property expansion through U.S. patents. Company releases emphasize implant designs that match patient bone density, fusion and motion-preservation applications, and integrated biologic support for spinal fusion procedures.
Aurora Spine Corporation (OTCQB: ASAPF) has obtained Institutional Review Board (IRB) approval for a multicenter clinical study of its ZIP® Interspinous Fixation device, aimed at treating back pain from degenerative disc disease. This study will involve 100 patients, with results expected within the year. The ZIP® device has already been used in over 5,000 procedures globally, showcasing its effectiveness in outpatient settings. Aurora partners with Celéri Health for data management, intending to enhance the treatment of chronic back pain through rigorous clinical research.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Spring 2021 Investor Conference on March 30, 2021, at 1:15 PM ET. The company's President & CEO, Trent Northcutt, and CFO, Chad Clouse, will present and engage in virtual one-on-one meetings from March 30 to April 1, 2021. A live webcast of the presentation will be accessible on their website, with an archived version available later. Aurora Spine focuses on innovative spinal implant technologies and pain management solutions.
Aurora Spine Corporation announced the launch of its proprietary SiLO™ Posterior SI Joint Fusion System, designed for posterior sacroiliac joint fusion. This innovative system aims to enhance surgical outcomes through a single graft method made of human cortical bone. The Company also released a biomechanical whitepaper demonstrating that the SiLO graft effectively immobilizes the sacroiliac joint better than traditional rectangular grafts. The SI joint fusion market is projected to grow significantly, with an estimated value of $150 million to $250 million globally in 2019, indicating a high potential for Aurora's growth.
Aurora Spine Corporation announced that its common shares are now trading on the OTCQB Venture Market under the symbol ASAPF, enhancing accessibility for US investors. This move is aimed at improving Aurora's status as a publicly traded company and boosting investor awareness, which the company began in 2020. The management foresees this listing as timely, coinciding with plans to launch several new proprietary products in 2021.
For more information, visit OTC Markets.